Keywords: nice, backs, taxol, gemzar, navelbine, first-line, chemotherapy
NICE backs Taxol, Gemzar and Navelbine as first-line chemotherapy in NSCLC
Article | 13 June 2001
The National Institute for Clinical Excellence has backed the use ofBristol-Myers Squibb's Taxol (paclitaxel), Eli Lilly's Gemzar (gemcitabine) and bioMerieux-Pierre ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
